Evidence
Mult Scler Relat Disord. 2023 Jul 2;77:104869. doi: 10.1016/j.msard.2023.104869. Online ahead of print.
ABSTRACT
BACKGROUND: Patient stratification and individualized treatment decisions based on multiple sclerosis (MS) clinical phenotypes are arbitrary. Subtype and Staging Inference (SuStaIn), a published machine learning algorithm, was developed to identify data-driven disease subtypes with distinct temporal progression patterns using brain magnetic resonance imaging; its clinical utility has not been assessed. The objective of this study was to explore the prognostic capability of SuStaIn subtyping and whether it is a useful personalized predictor of treatment effects of natalizumab and dimethyl fumarate.
METHODS: Subtypes were available from the trained SuStaIn model for 3 phase 3 clinical trials in relapsing-remitting and secondary progressive MS. Regression models were used to determine whether baseline SuStaIn subtypes could predict on-study clinical and radiological disease activity and progression. Differences in treatment responses relative to placebo between subtypes were determined using interaction terms between treatment and subtype.
RESULTS: Natalizumab and dimethyl fumarate reduced inflammatory disease activity in all SuStaIn subtypes (all p < 0.001). SuStaIn MS subtyping alone did not discriminate responder heterogeneity based on new lesion formation and disease progression (p > 0.05 across subtypes).
CONCLUSION: SuStaIn subtypes correlated with disease severity and functional impairment at baseline but were not predictive of disability progression and could not discriminate treatment response heterogeneity.
PMID:37459715 | DOI:10.1016/j.msard.2023.104869
Add to Google Keep
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Assessing the utility of magnetic resonance imaging-based “SuStaIn” disease subtyping for precision medicine in relapsing-remitting and secondary progressive multiple sclerosis
🌐 90 Days
Evidence Blueprint
Assessing the utility of magnetic resonance imaging-based “SuStaIn” disease subtyping for precision medicine in relapsing-remitting and secondary progressive multiple sclerosis
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence